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Abstract
Background: Plasmablastic lymphoma is an aggressive variant of diffuse large B cell lymphoma, mostly found in
the oral cavity and associated with human immunodeficiency virus. There are no clear guidelines for its treatment.
Therapies more intensive than cyclophosphamide, doxorubicin, vincristine, and prednisone are not associated with
a prolonged survival. Lymphomas of the breast are rare, in one series representing 0.14% of all female breast
malignancies, with diffuse large B cell lymphoma comprising up to 55% of all cases. Only one case of plasmablastic
lymphoma involving the breast has been reported in the literature.
Case presentation: A 30 year old Pakistani woman, presented with a small nodule in the floor of the mouth. An
excisional biopsy revealed CD20, CD3, and CD117 negative and CD138, CD79a, CD56, MUM1/IFR4 and CD30
positive lesion with Ki-67 of 60% with cells which were plasmablastic in appearance. The morphological and
immunohistochemistry features were consistent with plasmablastic lymphoma. The staging scans did not reveal any
lymphadenopathy and the bone marrow biopsy and human immunodeficiency virus test were both negative. After
treatment with four courses of CHOP and later radiation to the floor of the mouth, her disease was in complete
remission. Two months later, she presented with velvety red lesions in both breasts and its trucut biopsy was
consistent with plasmablastic lymphoma. Her CT scans revealed multiple nodules involving both breasts with no
lymphadenopathy. The bone marrow was now positive for disease. Her disease continued to progress despite
second and third line chemotherapy with DHAP (dexamethasone, cisplatin and cytarabine) and ICE (ifosfamide,
carboplatin and etoposide) respectively. Her last CT scans revealed progressive disease with new lung lesions. The
patient decided to opt for best supportive care.
Conclusion: To our knowledge this is the second report of plasmablastic lymphoma involving the breast. The
patient who was human immunodeficiency virus negative and immune competent had progressive disease despite
three lines of chemotherapies with an overall survival (to date) of 15 months.
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Background
Plasmablastic lymphoma (PBL) is a rare variant of Diffuse large B cell lymphoma, mostly found in the oral
cavity [1] and associated with human immunodeficiency
virus (HIV). Other rare sites of its occurrence include
oropharynx, nasopharynx, stomach, skin, lungs, sacrococcygeal, pericardial, anorectal, nasal, paranasal or submandibular regions [2]. Lymphoma of the breast is a
rare entity; representing 0.14% of all female breast malignancies [3]. However, amongst the breast lymphomas,
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the most common type is diffuse large B cell lymphoma
involving up to 55% of all cases. This subtype usually
occurs in women of older age, with slight predominance
of right side [3]. Other rare types of lymphomas to involve the breast are Burkitt’s lymphoma, Extranodal
marginal zone B cell lymphoma of mucosa associated
lymphoid tissue (MALT) type, follicular lymphoma, and
very rarely, T-cell lymphomas. Lymphomas involving the
breast are very rare, yet very aggressive. Hence they need
to be treated with combination chemotherapy with or
without local irradiation. In case of progression or relapse, the response to salvage therapy is poor [3].
Herein, we present a case of a 30 year old HIVnegative immunocompetent woman, who presented with
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a nodule in the floor of the mouth. A histopathological
diagnosis of PBL was made and she was treated with
chemotherapy followed by local radiation. She later presented with disease relapse in the breast. To our knowledge this is the second report of PBL involving the
breast [4].

Case presentation
A 30 year old Pakistani woman, presented with few
weeks history of dysphagia. Clinically she was well preserved and examination revealed small firm 1 cm nodule
on the floor of the mouth. The excisional biopsy thus
performed revealed neoplastic cells, which were arranged in diffuse sheets and were plasmablastic in appearance with vesicular nuclei, and centrally located
prominent nucleolus, with abundant basophilic cytoplasm (Figure 1). On immunohistochemistry these plasmacytoid cells were negative for conventional B cell
marker CD20 while pan T CD 3 was also negative.
These cells showed strong positivity for CD138, CD79a,
CD56, and MUM1/IFR4 with Ki-67 of approximately
60% (Figures 2, 3 and 4). The morphological and immunohistochemistry features were consistent with PBL. The
rest of her systemic examination was unremarkable. The
CT scan of head, neck, chest, abdomen and pelvis with
contrast did not reveal any lymphadenopathy and the
bone marrow biopsy was negative for disease. Patient
was tested to be negative for HIV. She did not have any
other condition which could compromise her immunity.
Her last pregnancy was about eight years back. She was
treated with standard CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy.
She had no evidence of disease at the time of initiation
of chemotherapy and remained in remission after 4
courses of CHOP; hence, treatment was consolidated
with local radiation. Two months later, she presented

Figure 1 H&E (hematoxylin and eosin) image shows large sheets of
mostly large plasmacytoid appearing mononuclear cells.

Figure 2 CD79a, immunohistochemical stain demonstrates
plasmacytic differentiation.

with self-discovered lumps in both breasts. It was not associated with pain or nipple discharge. Examination revealed diffuse erythema of the skin of both breasts with
peau-d-orange and velvety red lesions. The rest of her
systemic examination was unremarkable. She did not
have any high risk features for breast cancer such as history of oral contraceptive usage, personal or family history of breast cancer. A trucut biopsy of the breast
lesions was consistent with the prior diagnosis of plasmablastic lymphoma (Figure 5). Her CT scans of head,
neck, chest, abdomen and pelvis with contrast revealed
multiple rounded soft tissue density nodules involving
both breasts with no lymphadenopathy. The bone marrow was now positive for disease and was weakly positive for CD56. She received four courses of DHAP
(dexamethasone, cisplatin and cytarabine). She had good
clinical and radiological response to chemotherapy initially however by the end of four courses, her breast

Figure 3 CD138, immunohistochemical stain demonstrates
plasmacytic differentiation.
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Figure 4 MUM1/IRF4 shows positivity in neoplastic cells.

lesions recurred. She was then switched to third line
chemotherapy with ICE (ifosfamide, cyclophosphamide
and etoposide). Her breast lesions initially regressed but
grew before next cycle of chemotherapy in 2 weeks’
time. Her CT scans of head, neck, chest, abdomen and
pelvis with contrast revealed progressive disease with
increase in the number of breast lesions with new development of pleural effusion and multiple lung nodules
bilaterally. Further treatment options were discussed but
considering futility of treatment only best supportive
care was pursued and she went back to her native town.

Discussion
Plasmablastic lymphoma is usually associated with HIV
infection, where it accounts for 2.6% of all HIV related
Non-Hodgkin’s lymphomas [5]. However it may be
present in patients who are HIV negative but otherwise
immunocompromised, such as patients who have undergone solid organ transplantation or bone marrow transplantation or those with autoimmune disease [2]. It was
in 1997 when Delecluse and colleagues reported the first
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series of sixteen patients with diffuse large B cell lymphoma of oral cavity with unique immunohistochemical
features [6]. Based on their morphologic and immunohistologic features these tumors were named plasmablastic lymphoma [6]. PBL is said to be derived from post
germinal-center activated B cells, which are terminally
differentiated, believed to be in evolution from immunoblast to plasma cell [7]. PBL reveal little to no expression
of leukocyte common antigen (CD45) or the B-cell
markers CD20 and CD79a. However, there is almost
unanimous expression of plasma cell markers VS38c,
CD38, multiple myeloma oncogene-1 (MUM1/IRF4),
and CD138 (syndecan-1) [8].
Plasmablastic lymphoma has a very aggressive clinical
course with a median overall survival of about fifteen
months [8]. There are no clear guidelines for its treatment. Therapies more intensive than CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) are
not associated with a prolonged survival [9]. There are
several features associated with better survival, which
include the clinical stage, use of antiretroviral therapy
(in HIV patients) and achievement of complete response
to chemotherapy [9]. Autologous stem cell transplantation has been tried in such patients however the follow
up data has been too short to conclude it being effective
[10]. Bortezomib, a proteasome inhibitor may be a new
therapeutic option for plasmablastic lymphoma, which
has resulted in dramatic responses, however, the response has not been sustained [11].

Conclusion
In conclusion we report a case of plasmablastic lymphoma of the breast which initially presented with a hard
palate lesion. Our case was unique in presentation that
there was no evidence of disease after excisional biopsy
of hard palate and at recurrence breast was the only site.
Later however she also developed bilateral lung nodules
and pleural effusion. To our knowledge this is the
second reported case of PBL involving the breast [4] and
the first case report of how PBL of the breast was
treated.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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Figure 5 Breast biopsy shows involvement by plasmablastic
lymphoma.
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